4 OCTOBER

NEW ZEALAND GAZETTE

Piracetam
Promethazine; for injection
Rimiterol
Rifapentine
Salbutamol; for oral use
Salcatonin
Tasonermin
Terbutaline; for oral use
Tiemonium
Tigloidine
Tiotropium
Tricyclamol
Tridihexethyl
Trometamol; for injection in medicines containing more
than 3%
Verteporfin
Voriconazole
Zoledronic acid

Schedule 2
Restricted Medicines
*Triamcinolone; in aqueous nasal sprays delivering up
to 55 micrograms per actuation when the maximum
recommended daily dose is no greater than 220
micrograms and the medicine has received the consent of
the Minister or the Director-General to its distribution as
a restricted medicine.

Schedule 3
Pharmacy-only Medicines
Acetylcysteine; for oral use
Aconite; for oral use in packs containing 0.2 milligrams or
less and more than 0.02 milligrams of total alkaloids; for
dermal use in concentrations of 0.02% or less and in
packs containing not more than 0.2 milligrams of total
alkaloids.
Cyclizine; except for injection
Glyceryl trinitrate; for oral or rectal use; except in medicines
containing 100 micrograms or less per litre or per
kilogram
Hydrocyanic acid; for oral use in packs containing
5 milligrams or less and more than 0.5 milligrams;
except in medicines containing 1 microgram or less per
litre or per kilogram
Injectable medicines; except when specified elsewhere in
this Schedule; except Factor VIII; except for contrast
media, parenteral nutrition replacement preparations or
plasma volume expanders
Isosorbide dinitrate; for oral use in medicines containing
10 milligrams or less per dose form
Lithium; for dermal use in medicines containing 1% or less
and more than 0.01%
Loperamide; in packs containing not more than 20 tablets or
capsules
Pseudoephedrine; in cough or decongestant medicines
containing not more than 240 milligrams per
recommended daily dose either: in slow release
preparations; or in liquid preparations containing not
more than 60 milligrams per recommended dose; or
when compounded with other active ingredients; or in
solid dose form with no other active ingredients and
containing not more than 60 milligrams per
recommended dose and in packs containing not more
than 30 dose units.

3465

Medicines for General Sale
Please note that the following medicines are no longer
classified as prescription medicines, restricted medicines or
pharmacy-only medicines. As such, they are now available
for general sale.
Acetylcysteine; for external use
Aconite; for oral use in packs containing 0.02 milligrams or
less of total alkaloids; for dermal use in concentrations
of 0.02% or less and in packs containing not more than
0.02 milligrams of total alkaloids
Alcohol; except for injection in medicines containing more
than 20%
Factor VIII
Fluorescein; except for injection
Hyaluronic acid; except for injection
Hydrocyanic acid; for oral use in packs containing
0.5 milligrams or less; in medicines containing
1 microgram or less per litre or per kilogram
Injectable medicines which contain Factor VIII or which are
parenteral nutrition replacement preparations, plasma
volume expanders or contrast media
Lithium; for dermal use in medicines containing 0.01% or
less
Trichloroacetic acid
Trometamol; except for injection in medicines containing
more than 3%

Dated this 29th day of September 2001.
G. R. BOYD, Chief Advisor, Safety and Regulation
(pursuant to delegation given by the Minister of Health on
the 20th day of February 1997).

*Regulation 20 of the Medicines Regulations 1984 requires that all
medicines sold without a practitioner’s prescription must include a
consumer information panel on the label. Further, all material changes to a
medicine (including changes to labelling), must be notified to the
Director-General of Health in accordance with section 24 of the Medicines
Act 1981.

go6963

Misuse of Drugs Act 1975
Medical Practitioner Who May Prescribe,
Administer, or Supply Controlled Drugs for the
Purpose of Treating People with Drug Dependence
Pursuant to section 24 (5) (a) of the Misuse of Drugs Act
1975, I, Dr David George Chaplow, acting under the
delegated authority of the Minister of Health, hereby
approve
Dr Mark Britten Winter, medical practitioner at
Harewood Road Medical Centre, 171 Harewood
Road, Christchurch
as a medical practitioner who may prescribe, administer, or
supply controlled drugs for the purposes of that section,
subject to the following specific conditions:

1. Prescription of controlled drugs is limited to the drug
   methadone;
2. prescription of methadone may only be made to
   patients registered at Dr Winter’s practice who have
   been assessed by a gazetted methadone service; and
3. only designated locums working in Dr Winter’s
   practice, but no other medical practitioners, may
   prescribe methadone to Dr Winter’s patients with
   Dr Winter’s permission in writing.

Dated at Wellington this 1st day of October 2001.
DR DAVID CHAPLOW, Director of Mental Health.

go7008